ArticleBMC chemistry2025
Greenness and whiteness profiles of a validated HPTLC method for the simultaneous analysis of clopidogrel and rosuvastatin in fixed-dose combination capsules.
Article in BMC chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The goal of the current work was to create and validate a quick, sensitive, and environmentally friendly reverse-phase "high-performance thin-layer chromatography (HPTLC)" approach for the simultaneous measurement of rosuvastatin (ROS) and clopidogrel (CLOP) in their fixed-dose combination (FDC) capsules. Eight different greenness and whiteness tools, such as the analytical eco-scale (AES), chloroform toxicity (ChlorTox), the analytical GREEnness (AGREE), the modified green analytical procedure index (MoGAPI), the complex MoGAPI, the blue applicability grade index (BAGI), the carbon footprint reduction index (CaFRI), and the click analytical chemistry index (CACI) were utilized to evaluate the method's greenness and whiteness profiles. The suggested strategy was linear for both medications in the 25-1000 ng/band level. The method was proven to be reliable, sensitive, accurate, precise, and eco-friendly. The results of greenness and whiteness tools, such as AES (87), ChlorTox (0.86 g), AGREE (0.72), MoGAPI (85), complex MoGAPI (90), BAGI (77.5), CaFRI (89), and CACI (91) demonstrated that the current method had the unparalleled greenness and whiteness profiles. Using the proposed methodology, it was found that the assay of CLOP and ROS in FDC products A and B was ranged from 98.41 to 101.02%. These results confirm that the suggested approach is appropriate for concurrently analyzing ROS and CLOP. The work's findings showed that the suggested approach might be used to consistently analyze CLOP and ROS in commercial dosage forms.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.